Table 1.
The comparisons of patients with SSHL and control subjects
| Parameters | SSHL (N: 147) | Control group (N: 103) | P |
|---|---|---|---|
| Age range (year) | 15–55 | 17–51 | – |
| Mean age (year) | 30.81 ± 11.08 | 30.11 ± 10.27 | – |
| Gender (M/F) | 79/68 | 55/48 | – |
| Duration of treatment onset (day) | 1–20 (7.63 ± 5.21) | – | – |
| MCV (femtoliter) | 81.72 ± 8.02 | 83.1 ± 5.07 | .582 |
| Hemoglobin (g/dl) | 14.21 ± 1.25 | 15.78 ± 1.32 | .001* |
| Haematocrit (%) | 40.61 ± 4.11 | 45.82 ± 3.25 | .011* |
| RDW (%) | 13.87 ± 1.46 | 13.01 ± 0.89 | .097 |
| Platelet (103/μl) | 256.39 ± 58.19 | 251.27 ± 56.07 | .580 |
| WBC (103/μl) | 8.51 ± 2.32 | 7.98 ± 2.12 | .032* |
| Total Bilirubin (mg/dl) | 0.60 ± 0.35 | 0.86 ± 0.39 | .023* |
| Direct Bilirubin (mg/dl) | 0.20 ± 0.15 | 0.34 ± 0.17 | .001* |
| Indirect Bilirubin (mg/dl) | 0.40 ± 0.21 | 0.49 ± 0.34 | .291 |
| Fasting blood glucose (mg/dl) | 112.65 ± 53.20 | 90.08 ± 7.98 | .030* |
| BUN (mg/dl) | 19.01 ± 15.26 | 19.65 ± 12.81 | .921 |
| Creatinin (mg/dl) | 1.03 ± 1.24 | 0.95 ± 0.31 | .524 |
| Total lipid (mg/dl) | 173.74 ± 37.15 | 150.61 ± 40.94 | .212 |
| Triglyceride (mg/dl) | 173.96 ± 120.17 | 124.19 ± 86.55 | .308 |
| HDL (mg/dl) | 43.62 ± 12.85 | 41.22 ± 9.08 | .815 |
| LDL (mg/dl) | 96.39 ± 35.80 | 84.25 ± 33.21 | .427 |
| VLDL (mg/dl) | 36.61 ± 26.87 | 26.80 ± 18.74 | .329 |
| AST (u/l) | 26.45 ± 8.60 | 22.84 ± 6.46 | .041* |
| ALT (u/l) | 24.85 ± 12.76 | 24.12 ± 14.91 | .756 |
MCV mean corpuscular volume, RDW red cell distribution width, WBC white blood cell count, BUN blood urea nitrogen, HDL: high density lipoprotein, LDL low density lipoprotein, VLDL: very low density lipoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase
* Statistically significant